Appreciate very much this clear and well-written summary! Thank you to all involved.
#kidneycancer
@ikccorg.bsky.social
#ESMO26
#kidneycancer
@ikccorg.bsky.social
#ESMO26
November 2, 2026 at 2:55 PM
Appreciate very much this clear and well-written summary! Thank you to all involved.
#kidneycancer
@ikccorg.bsky.social
#ESMO26
#kidneycancer
@ikccorg.bsky.social
#ESMO26
Visit www.esmo.org/insights-by-... for reviewing the most impactful communications #ESMO26 & to keep up with info on #cancerresearch advances all year long
News and Insights | ESMO
www.esmo.org
October 31, 2026 at 12:01 PM
Visit www.esmo.org/insights-by-... for reviewing the most impactful communications #ESMO26 & to keep up with info on #cancerresearch advances all year long
#ESMO26 Round Up: Six Original Articles were simultaneously published in NEJM and presented at this year’s European Society of Medical Oncology (@myesmo.bsky.social) Congress in Madrid.
October 28, 2026 at 4:46 PM
"Something we have not seen for years." -- Nathalie Gaspar, MD, PhD, of @gustaveroussy.fr, on positive phase III trial results for an investigational osteosarcoma drug tested in adolescents and adults. #ESMO26 @myesmo.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma
Novel B7-H3-targeted drug significantly improved progression-free survival versus chemotherapy
www.medpagetoday.com
November 2, 2026 at 2:55 PM
"Something we have not seen for years." -- Nathalie Gaspar, MD, PhD, of @gustaveroussy.fr, on positive phase III trial results for an investigational osteosarcoma drug tested in adolescents and adults. #ESMO26 @myesmo.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
#ESMO26: Phase III OptiTROP-Lung06 #ClinicalTrial reports a game-changing 51% reduction in the risk of progression or death with the #ADC sacituzumab tirumotecan added to pembrolizumab in advanced #NSCLC
➡️ https://ow.ly/4I5Y5102qBk
#InsightsbyESMO
➡️ https://ow.ly/4I5Y5102qBk
#InsightsbyESMO
October 30, 2026 at 1:20 PM
#ESMO26: Phase III OptiTROP-Lung06 #ClinicalTrial reports a game-changing 51% reduction in the risk of progression or death with the #ADC sacituzumab tirumotecan added to pembrolizumab in advanced #NSCLC
➡️ https://ow.ly/4I5Y5102qBk
#InsightsbyESMO
➡️ https://ow.ly/4I5Y5102qBk
#InsightsbyESMO
Some 📝 #ESMO26 #Madrid
➡️Growing new 🎯 GPC3, GUCY2C...
➡️RAS targeting is the new normal
➡️Novel technologies will improve cancer outcomes to levels never known bf
⚠️our health systems will struggle
To avoid increasing inequalities, optimisation of resources is key! @myesmo.bsky.social
➡️Growing new 🎯 GPC3, GUCY2C...
➡️RAS targeting is the new normal
➡️Novel technologies will improve cancer outcomes to levels never known bf
⚠️our health systems will struggle
To avoid increasing inequalities, optimisation of resources is key! @myesmo.bsky.social
October 31, 2026 at 11:57 AM
Some 📝 #ESMO26 #Madrid
➡️Growing new 🎯 GPC3, GUCY2C...
➡️RAS targeting is the new normal
➡️Novel technologies will improve cancer outcomes to levels never known bf
⚠️our health systems will struggle
To avoid increasing inequalities, optimisation of resources is key! @myesmo.bsky.social
➡️Growing new 🎯 GPC3, GUCY2C...
➡️RAS targeting is the new normal
➡️Novel technologies will improve cancer outcomes to levels never known bf
⚠️our health systems will struggle
To avoid increasing inequalities, optimisation of resources is key! @myesmo.bsky.social
#ESMO26: Bi-weekly trifluridine–tipiracil plus bevacizumab was associated with similar overall survival and lower haematological toxicity than conventional dosing in patients with metastatic #ColorectalCancer in the PRABITAS #ClinicalTrial
🔗 https://ow.ly/nSyJ5100p1p
#InsightsbyESMO
🔗 https://ow.ly/nSyJ5100p1p
#InsightsbyESMO
October 28, 2026 at 1:45 PM
#ESMO26: Bi-weekly trifluridine–tipiracil plus bevacizumab was associated with similar overall survival and lower haematological toxicity than conventional dosing in patients with metastatic #ColorectalCancer in the PRABITAS #ClinicalTrial
🔗 https://ow.ly/nSyJ5100p1p
#InsightsbyESMO
🔗 https://ow.ly/nSyJ5100p1p
#InsightsbyESMO
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
October 29, 2026 at 5:14 PM
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#ESMO26 Round Up: Six Original Articles were simultaneously published in NEJM and presented at this year’s European Society of Medical Oncology (@myesmo.bsky.social) Congress in Madrid.
October 27, 2026 at 7:10 PM
#ESMO26 Round Up: Six Original Articles were simultaneously published in NEJM and presented at this year’s European Society of Medical Oncology (@myesmo.bsky.social) Congress in Madrid.
#ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50%
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
October 30, 2026 at 9:20 AM
#ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50%
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
➡️ https://ow.ly/eWmC5100p3O
#InsightsbyESMO
Alfredo Addeo
As myesmo.bsky.social Congress 2026 closes, advances in cancer care remain in focus.
From antibody–drug conjugates to machine learning in cancer risk prediction, explore the latest with EMJ.
www.emjreviews.com/therapeutic-...
#ESMO26 #Oncology
From antibody–drug conjugates to machine learning in cancer risk prediction, explore the latest with EMJ.
www.emjreviews.com/therapeutic-...
#ESMO26 #Oncology
October 28, 2026 at 9:57 AM
As myesmo.bsky.social Congress 2026 closes, advances in cancer care remain in focus.
From antibody–drug conjugates to machine learning in cancer risk prediction, explore the latest with EMJ.
www.emjreviews.com/therapeutic-...
#ESMO26 #Oncology
From antibody–drug conjugates to machine learning in cancer risk prediction, explore the latest with EMJ.
www.emjreviews.com/therapeutic-...
#ESMO26 #Oncology
Not everyone is in the photo due to busy schedules at #ESMO26, but still #ESMOcommunity
#ESMOAmbassadors @myesmo.bsky.social @acammarota.bsky.social
#ESMOAmbassadors @myesmo.bsky.social @acammarota.bsky.social
October 27, 2026 at 1:15 PM
Not everyone is in the photo due to busy schedules at #ESMO26, but still #ESMOcommunity
#ESMOAmbassadors @myesmo.bsky.social @acammarota.bsky.social
#ESMOAmbassadors @myesmo.bsky.social @acammarota.bsky.social
Intensified adjuvant chemotherapy did not improve disease-free survival compared with standard chemotherapy in patients with high-risk stage III colon cancer, the phase III IROCAS trial showed. #ESMO26 https://www.medpagetoday.com/meetingcoverage/esmo/123646
Intensified Adjuvant Chemo No Better Than Standard in High-Risk Colon Cancer
Modified FOLFIRINOX failed to improve disease-free survival in stage III disease
www.medpagetoday.com
October 30, 2026 at 1:32 PM
Intensified adjuvant chemotherapy did not improve disease-free survival compared with standard chemotherapy in patients with high-risk stage III colon cancer, the phase III IROCAS trial showed. #ESMO26 https://www.medpagetoday.com/meetingcoverage/esmo/123646
Catch up on the cancer research MSK presented at #ESMO26. 🔬
Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma.
Learn more: https://bit.ly/4jPdNco
Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma.
Learn more: https://bit.ly/4jPdNco
October 30, 2026 at 4:05 PM
Catch up on the cancer research MSK presented at #ESMO26. 🔬
Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma.
Learn more: https://bit.ly/4jPdNco
Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma.
Learn more: https://bit.ly/4jPdNco
To read the full publication, click link in bio or go to https://ow.ly/tbs75102zs1.
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
October 31, 2026 at 6:00 PM
To read the full publication, click link in bio or go to https://ow.ly/tbs75102zs1.
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
October 29, 2026 at 2:10 PM
#ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
Explore selected research presented at #ESMO26 across five live Congress Highlights Webinars, with expert discussion and interactive Q&A.
📅 9-13 November, daily at 18:30 CET
Register: https://ow.ly/zfYs50ZY4kx
#ESMOOnAir #CongressHighlights
📅 9-13 November, daily at 18:30 CET
Register: https://ow.ly/zfYs50ZY4kx
#ESMOOnAir #CongressHighlights
October 27, 2026 at 8:30 AM
Explore selected research presented at #ESMO26 across five live Congress Highlights Webinars, with expert discussion and interactive Q&A.
📅 9-13 November, daily at 18:30 CET
Register: https://ow.ly/zfYs50ZY4kx
#ESMOOnAir #CongressHighlights
📅 9-13 November, daily at 18:30 CET
Register: https://ow.ly/zfYs50ZY4kx
#ESMOOnAir #CongressHighlights
#ESMO26: Belzutifan does not improve survival as first-line treatment for advanced clear-cell renal cell carcinoma (#RCC) in the phase III LITESPARK-012 #ClinicalTrial but shows promise in later lines in LITESPARK-011.
➡️Read more #InsightsbyESMO: https://ow.ly/QY4l5100p1t
➡️Read more #InsightsbyESMO: https://ow.ly/QY4l5100p1t
October 29, 2026 at 8:30 AM
#ESMO26: Belzutifan does not improve survival as first-line treatment for advanced clear-cell renal cell carcinoma (#RCC) in the phase III LITESPARK-012 #ClinicalTrial but shows promise in later lines in LITESPARK-011.
➡️Read more #InsightsbyESMO: https://ow.ly/QY4l5100p1t
➡️Read more #InsightsbyESMO: https://ow.ly/QY4l5100p1t
Explore timely, on-the-ground coverage of key trials presented at #ESMO26 with VJ Oncology 👉 bit.ly/4jpTaTQ
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology. Visit the @VJOncology website to watch the latest coverage!
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology. Visit the @VJOncology website to watch the latest coverage!
November 2, 2026 at 2:59 PM
Explore timely, on-the-ground coverage of key trials presented at #ESMO26 with VJ Oncology 👉 bit.ly/4jpTaTQ
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology. Visit the @VJOncology website to watch the latest coverage!
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology. Visit the @VJOncology website to watch the latest coverage!
To read the full publication, click link in bio or go to https://ow.ly/3Jwt5102yTL.
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
October 30, 2026 at 10:00 PM
To read the full publication, click link in bio or go to https://ow.ly/3Jwt5102yTL.
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26
#ESMO26: Next-generation CDK4 inhibitor atirmociclib in combination with fulvestrant extends PFS by 3 months in endocrine-resistant #AdvancedBreastCancer in the phase II FOURLIGHT-1 #ClinicalTrial
🔗 https://ow.ly/RU1s5100p0G
#InsightsbyESMO #BreastCancer
🔗 https://ow.ly/RU1s5100p0G
#InsightsbyESMO #BreastCancer
October 28, 2026 at 9:00 AM
#ESMO26: Next-generation CDK4 inhibitor atirmociclib in combination with fulvestrant extends PFS by 3 months in endocrine-resistant #AdvancedBreastCancer in the phase II FOURLIGHT-1 #ClinicalTrial
🔗 https://ow.ly/RU1s5100p0G
#InsightsbyESMO #BreastCancer
🔗 https://ow.ly/RU1s5100p0G
#InsightsbyESMO #BreastCancer
#ESMO26: Navigating the beneficial use of #AI for #RealWorldEvidence generation while retaining GDPR compliance is a delicate balance. Rodrigo Dienstmann
discusses how federated learning platforms can help
#InsightsbyESMO ➡️ https://ow.ly/7On05100ZQr
#HealthcareInnovation
discusses how federated learning platforms can help
#InsightsbyESMO ➡️ https://ow.ly/7On05100ZQr
#HealthcareInnovation
October 27, 2026 at 7:00 PM
#ESMO26: Navigating the beneficial use of #AI for #RealWorldEvidence generation while retaining GDPR compliance is a delicate balance. Rodrigo Dienstmann
discusses how federated learning platforms can help
#InsightsbyESMO ➡️ https://ow.ly/7On05100ZQr
#HealthcareInnovation
discusses how federated learning platforms can help
#InsightsbyESMO ➡️ https://ow.ly/7On05100ZQr
#HealthcareInnovation
DESTINY-Breast11 presented at #ESMO26 shows promise in treating HER2+ early #BreastCancer:
📈T-DXd-THP had higher ORRs when compared to ddAC-THP: 92.9% vs 87.2%
Presented by Jean-François Boileau, MD, at @myesmo.bsky.social Congress 2026
Read more! 🔽
https://bit.ly/4sB3FX7
📈T-DXd-THP had higher ORRs when compared to ddAC-THP: 92.9% vs 87.2%
Presented by Jean-François Boileau, MD, at @myesmo.bsky.social Congress 2026
Read more! 🔽
https://bit.ly/4sB3FX7
November 2, 2026 at 11:13 PM
DESTINY-Breast11 presented at #ESMO26 shows promise in treating HER2+ early #BreastCancer:
📈T-DXd-THP had higher ORRs when compared to ddAC-THP: 92.9% vs 87.2%
Presented by Jean-François Boileau, MD, at @myesmo.bsky.social Congress 2026
Read more! 🔽
https://bit.ly/4sB3FX7
📈T-DXd-THP had higher ORRs when compared to ddAC-THP: 92.9% vs 87.2%
Presented by Jean-François Boileau, MD, at @myesmo.bsky.social Congress 2026
Read more! 🔽
https://bit.ly/4sB3FX7
#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
October 27, 2026 at 11:00 AM
#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
#ESMO26: Novel targeted treatments, including antibody–drug conjugates (#ADCs) and bispecific antibodies, show good responses in #immunotherapy-resistant #melanoma, although toxicity and cost are potential concerns.
Read more:
🔗 https://ow.ly/fv2I5100nzS
#InsightsbyESMO
Read more:
🔗 https://ow.ly/fv2I5100nzS
#InsightsbyESMO
October 27, 2026 at 3:30 PM
#ESMO26: Novel targeted treatments, including antibody–drug conjugates (#ADCs) and bispecific antibodies, show good responses in #immunotherapy-resistant #melanoma, although toxicity and cost are potential concerns.
Read more:
🔗 https://ow.ly/fv2I5100nzS
#InsightsbyESMO
Read more:
🔗 https://ow.ly/fv2I5100nzS
#InsightsbyESMO